PMID- 29808971
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20200311
IS  - 1827-1596 (Electronic)
IS  - 0375-9393 (Linking)
VI  - 85
IP  - 2
DP  - 2019 Feb
TI  - Single versus divided administration of intravenous immunoglobulin for sepsis: a 
      retrospective and historical control study.
PG  - 156-163
LID - 10.23736/S0375-9393.18.12344-3 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is regarded as effective, 
      theoretically, for sepsis. The IVIG regimen for severe infection covered by 
      Japanese health insurance is administration of 5 g/day for three days: an 
      extremely low dosage. We investigated its effectiveness by comparison between 
      divided dosage and single dosage of 15 g for one day. METHODS: Patients who were 
      admitted to our hospital's Emergency Medical Center and treated with IVIG for 
      sepsis were included and were analyzed retrospectively. The dosage regimen was 5 
      g for three days in the early half period, and 15 g for one day in the latter 
      half period employing the same indication criteria. RESULTS: Each group included 
      57 patients. No significant difference was found in their baseline 
      characteristics, survival probability, or length of mechanical ventilation. 
      However, the ICU stay and hospital stay lengths were shortened significantly by 
      administration of the single dosage regimen. Disseminated intravascular 
      coagulopathy markers and inflammatory indices were improved significantly earlier 
      in the 15 g for one day group. Regarding adverse events, no significant 
      difference was found. CONCLUSIONS: For sepsis treatment, single administration of 
      15 g IVIG for one day improved the condition and inflammation earlier than 
      divided dosage.
FAU - Nakamura, Kensuke
AU  - Nakamura K
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan - mamashockpapashock@yahoo.co.jp.
FAU - Inokuchi, Ryota
AU  - Inokuchi R
AD  - Department of Emergency and Critical Care Medicine, The University of Tokyo 
      Hospital, Tokyo, Japan.
FAU - Fukushima, Kazutaka
AU  - Fukushima K
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan.
FAU - Naraba, Hiromu
AU  - Naraba H
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan.
FAU - Takahashi, Yuji
AU  - Takahashi Y
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan.
FAU - Sonoo, Tomohiro
AU  - Sonoo T
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan.
FAU - Hashimoto, Hideki
AU  - Hashimoto H
AD  - Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 
      Hitachi, Japan.
FAU - Doi, Kent
AU  - Doi K
AD  - Department of Emergency and Critical Care Medicine, The University of Tokyo 
      Hospital, Tokyo, Japan.
FAU - Morimura, Naoto
AU  - Morimura N
AD  - Department of Emergency and Critical Care Medicine, The University of Tokyo 
      Hospital, Tokyo, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180528
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - Minerva Anestesiol. 2019 Feb;85(2):115-117. PMID: 30394078
MH  - Aged
MH  - Aged, 80 and over
MH  - Critical Care
MH  - Disseminated Intravascular Coagulation
MH  - Female
MH  - Historically Controlled Study
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/*therapeutic use
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Respiration, Artificial
MH  - Retrospective Studies
MH  - Sepsis/*drug therapy
MH  - Survival Analysis
EDAT- 2018/05/29 06:00
MHDA- 2020/03/12 06:00
CRDT- 2018/05/30 06:00
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2018/05/30 06:00 [entrez]
AID - S0375-9393.18.12344-3 [pii]
AID - 10.23736/S0375-9393.18.12344-3 [doi]
PST - ppublish
SO  - Minerva Anestesiol. 2019 Feb;85(2):156-163. doi: 10.23736/S0375-9393.18.12344-3. 
      Epub 2018 May 28.